Within individual PD patients, longitudinal increases over time, rather than absolute levels, of LEV-α-synuclein are more tightly associated with the progression of motor impairment, underscoring the advantage of a blood-based biomarker to track disease stage [100]. Here, SNCA is linked to Parkinson disease.